Dear Anfal,

Tried to answer this question.

In phase III clinical trials:

Perifosine, for colorectal cancer andmultiple myeloma. (discontinued 2013)

Idelalisib also for chronic lymphocytic leukaemia.  Trials for CLL terminated/abandoned in 2015.

Idelalisib for indolent non-Hodgkin lymphoma.

Buparlisib (BKM120)[15][16] for HR+/HER2 advanced endocrine-resistant breast cancer - encouraging results in Dec 2015.

Duvelisib, (IPI-145) a novel inhibitor of PI3K delta and gamma, especially for hematologic malignancies and inflammatory conditions.  It is in 4 active phase 3 trials.

Alpelisib (BYL719), an alpha-specific PI3K inhibitor,  starting SOLAR-1 trial for PIK3CA-altered metastatic breast cancer. Trial to end July 2019. 

TGR 1202, oral PI3K delta inhibitor (previously known as RP5264) has shown promising efficacy with a superior toxicity profile compared with idelalisib.Now in ph3 for CLL. A 3 year data (inc Follicular Lymphoma and DLBCL) announced June 2016 for.Once daily administration.

Copanlisib (BAY 80-6946), predominantly inhibits PI3Kα,δ isoforms for indolent non-Hodgkin lymphoma.

In/starting phase II clinical trials.

Early stage

In early stage clinical trials 

Dactolisib...The first into clinical trials, in 2006. A PI3K/mTOR dual inhibitor.

RP6530, Dual PI3K delta/gamma inhibitor for lymphomas.

SF1126....Some early clinical data has been presented. First PI3KI 'Orphan Drug' for B-cell chronic lymphocytic leukemia (CLL). SF1126 is the first PI-3 kinase inhibitor to enter pediatric cancer clinical trials via the NANT consortium.

INK1117....in phase 1

GSK1059615 : The phase I trial of this drug was terminated due to lack of sufficient exposure following single- and repeat- dosing.

PWT33597, a dual PI3K-alpha/mTORinhibitor - for advanced solid tumors. IND mid 2011.and Phase I recruiting.

CUDC-907, Also an HDAC inhibitor. IND has been filed..In 2016 it was reported as showing promising preliminary evidence of response in patients with diffuse large B-cell lymphoma.

IPI-549, a PI3K-gamma inhibitor, in phase 1 for various cancers.

RP6503,Dual PI3K delta/gamma inhibitor for the treatment of Asthma and COPD (Late pre-clinical stage).

All the best

Thank you very much, I will test Duvelisib (IPI-145) with have shown most promising results until now. The other inhibitors have been tested.

Best Regards

Anfal H